Bristol-Myers Squibb: all 2,184 studies

Page 3 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisCompletedNCT04991935Phase 3Results posted
• A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy ParticipantsCompletedNCT04965389Phase 1Results posted
• A Study of CC-99677 in Participants With Active Ankylosing SpondylitisTerminatedNCT04947579Phase 2Results posted
• A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateActive, not recruitingNCT04909801Phase 3Results posted
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsActive, not recruitingNCT04908202Phase 3Results posted
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentActive, not recruitingNCT04908189Phase 3Results posted
• Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedNCT04887870Phase 2/3Results posted
• A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisCompletedNCT04877990Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)Active, not recruitingNCT04857034Phase 2Results posted
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)CompletedNCT04820309Phase 3Results posted
• A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadActive, not recruitingNCT04810078Phase 3Results posted
• A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic DermatitisCompletedNCT04800315Phase 2Results posted
• A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTCompletedNCT04766892Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisCompletedNCT04753697Phase 3Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)CompletedNCT04738123Phase 3Results posted
• A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerTerminatedNCT04730349Phase 1/2Results posted
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsActive, not recruitingNCT04717414Phase 3Results posted
• A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerCompletedNCT04702880Phase 2Results posted
• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationActive, not recruitingNCT04685135Phase 3Results posted
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)CompletedNCT04659174Phase 3Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)CompletedNCT04659161Phase 3Results posted
• A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)CompletedNCT04623775Phase 2Results posted
• A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT04613518Phase 2Results posted
• Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other CausalitiesTerminatedNCT04572893Phase 2Results posted
• A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsCompletedNCT04567615Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaCompletedNCT04513522Phase 4Results posted
• Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory CompromiseTerminatedNCT04472494Phase 2Results posted
• A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced CancersCompletedNCT04350463Phase 2Results posted
• Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsCompletedNCT04349267Phase 1/2Results posted
• A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction TherapyCompletedNCT04349072Phase 3Results posted
• A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerCompletedNCT04340193Phase 3Results posted
• Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart FailureCompletedNCT04318093Phase 2Results posted
• A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisCompletedNCT04308681Phase 2Results posted
• Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)TerminatedNCT04267393Phase 2Results posted
• A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerCompletedNCT04209114Phase 3Results posted
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCompletedNCT04186871Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaCompletedNCT04167462Phase 3Results posted
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTerminatedNCT04161391Phase 1/2Results posted
• A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)TerminatedNCT04149574Phase 3Results posted
• Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerCompletedNCT04109066Phase 3Results posted
• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerCompletedNCT04100018Phase 3Results posted
• Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingNCT04099251Phase 3Results posted
• A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTerminatedNCT04088500Phase 2Results posted
• A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCompletedNCT04075604Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedNCT04048876Phase 2Results posted
• A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results posted
• A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerActive, not recruitingNCT04025879Phase 3Results posted
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingNCT04008030Phase 3Results posted
• An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersCompletedNCT03994601Phase 1/2Results posted
• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3Results posted
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus NephritisTerminatedNCT03943147Phase 2Results posted
• Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT03934216Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisCompletedNCT03924427Phase 3Results posted
• Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusCompletedNCT03920267Phase 2Results posted
• Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03906071Phase 3Results posted
• An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell TransfusionCompletedNCT03900715Phase 2Results posted
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)CompletedNCT03881059Phase 2Results posted
• A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsCompletedNCT03792750Phase 1/2Results posted
• A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelCompletedNCT03766581Phase 2Results posted
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerTerminatedNCT03745222Phase 3Results posted
• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)TerminatedNCT03743246Phase 1/2Results posted
• An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop DiureticCompletedNCT03730961Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different ProcessesCompletedNCT03714022Phase 1Results posted
• Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCompletedNCT03703375Phase 3Results posted
• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With SchizophreniaCompletedNCT03697252Phase 2Results posted
• A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveActive, not recruitingNCT03682536Phase 3Results posted
• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2Results posted
• A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)CompletedNCT03668119Phase 2Results posted
• An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) CancersCompletedNCT03662659Phase 2Results posted
• A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)CompletedNCT03656718Phase 1/2Results posted
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaCompletedNCT03635983Phase 3Results posted
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedNCT03624127Phase 3Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03611751Phase 3Results posted
• A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03606174Phase 2Results posted
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseTerminatedNCT03599622Phase 2Results posted
• A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin LymphomasCompletedNCT03575351Phase 3Results posted
• A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTerminatedNCT03519256Phase 2Results posted
• Bioavailability of Apixaban Sprinkle Compared to Apixaban CapsulesCompletedNCT03509883Phase 1Results posted
• Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERCompletedNCT03496168Phase 2Results posted
• Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) InfectionTerminatedNCT03487848Phase 2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedNCT03486912Phase 2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedNCT03486899Phase 2Results posted
• Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin LymphomaCompletedNCT03484702Phase 2Results posted
• Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)CompletedNCT03483103Phase 2Results posted
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingNCT03470922Phase 2/3Results posted
• Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyCompletedNCT03470545Phase 3Results posted
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03467958Phase 3Results posted
• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03464097Phase 3Results posted
• An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT03459222Phase 1/2Results posted
• v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491CompletedNCT03447990Phase 1/2Results posted
• An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadTerminatedNCT03446040Phase 1/2Results posted
• Study of Nivolumab for Advanced Cancers in IndiaCompletedNCT03444766Phase 4Results posted
• A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)CompletedNCT03442764Phase 2Results posted
• Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseCompletedNCT03440385Phase 3Results posted
• Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03440372Phase 3Results posted
• Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03430011Phase 1/2Results posted
• A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis CCompletedNCT03420768Phase 2Results posted
• An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has SpreadCompletedNCT03414983Phase 2/3Results posted

← Bristol-Myers Squibb overview and focus areas